Dong-A ST KRW 81 billionㆍST Pharm KRW 65.5 billion
Eleven pharmaceutical and bio firms announced a total of KRW 2 trillion worth of new facility investment plans last year. (excluding corrective disclosure)
Among them, Samsung Biologics said that it would invest KRW 1.74 trillion to add a fourth plant at Songdo, Incheon, accounting for an absolute proportion of all, and ten other companies announced plans to invest about KRW 290 billion in facilities.
Along with Samsung Biologics, Dong-A ST announced that it would invest KRW 81 billion to build a new plant at Songdo, Incheon, and ST Pharm also unveiled plans to invest a total of KRW 65.5 billion in facilities in anticipation of demand for COVID-19 vaccine.
DAE HWA Pharmaceutical said that it would invest KRW 42 billion to build a fourth plant in Hoengseong, and Huons also revealed that it would invest KRW 39 billion in new facility investments to expand its production capacity.
Following this, DHP Korea released a plan to invest KRW 22.1 billion in introducing mechanical facility and factory expansion to increase production capacity, while Pharmicell planned to invest in expanding pharmaceutical raw material production facilities at Ulsan plant.
FutureChem’s investment will be used to build a new plant in Gijang, and Access Bio will invest KRW 7.8 billion in the purchase of automated production equipment to expand the production capacity of COVID-19 test kits.
Furthermore, Jetema said that it would invest KRW 7.4 billion in filler production facilities’ production capacity, and Bioneer announced to invest KRW 5.8 billion in expanding its production plant for molecular diagnostic products.
